<ul>
<li>这两项更新强调了 Teva 在其 “转型增长” 战略中的强大执行力和对财务纪律的承诺。</li>
<li>穆迪确认了 Teva 的 B1a 评级，并将 Teva 的展望从稳定调整为积极。</li>
<li>标普将 Teva 的评级从 BB 上调至 BB+，展望为稳定。</li>
</ul>
<p>以色列特拉维夫，2025 年 12 月 24 日（GLOBE NEWSWIRE）-- Teva 制药工业有限公司（纽约证券交易所和特拉维夫证券交易所：TEVA）今天宣布，标准普尔全球评级（&#34;S&amp;P&#34;）已将 Teva 的长期发行人信用评级从 ‘BB’ 上调至 ‘BB+’，展望为稳定，同时穆迪评级机构（&#34;Moody's&#34;）确认了 Teva 的 B1a 评级，并将 Teva 的展望从稳定调整为积极。这些升级标志着 Teva 在实现投资级别地位的旅程中的又一个重要里程碑。</p>
<p>这些升级得益于 Teva 持续的去杠杆化轨迹，标准普尔指出，截至 2025 年 9 月 30 日，调整后的杠杆率降至 4.4 倍，并预计在未来几个季度将降至 4.25 倍以下，符合更高评级的门槛。评级机构还强调了 Teva 的财务纪律、业务实力和流动性状况，在经历五年的下降后，重新实现了收入增长，这得益于品牌药物的强劲表现和仿制药的稳定。</p>
<p>穆迪提到 Teva 在运营表现和专注于减债的财务政策方面的持续改善。该机构强调了 Teva 品牌业务的强劲势头以及即将推出的品牌和生物类似药产品，这些预计将抵消仿制药领域的逆风。穆迪还指出 Teva 的强大流动性状况，支持其管理即将到期的债务的能力。穆迪表示，这些因素，加上预计杠杆将在 12 至 18 个月内降至 3.5 倍的预期，支撑了积极的展望和升级的潜力。</p>
<p><strong>Teva 首席财务官 Eli Kalif 评论道</strong>：&#34;这一升级是我们战略愿景和严谨执行的有力证明，尤其是在最近几个月多次升级之后。通过推动我们的转型增长战略，优先管理强劲的现金流，并严格分配资本，我们展示了对去杠杆化和可持续业务增长的坚定承诺。这些结果清楚地表明，我们的专注战略为 Teva 带来了切实的价值，并为我们持续的成功奠定了基础。&#34;</p>
<p><strong>关于 Teva</strong></p>
<p>Teva 制药工业有限公司（纽约证券交易所和特拉维夫证券交易所：TEVA）正在转型为一家领先的创新生物制药公司，依托于世界一流的仿制药业务。120 多年来，Teva 对改善健康的承诺从未动摇。从在神经科学和免疫学领域的创新，到向全球提供复杂的仿制药、生物类似药和药房品牌，Teva 致力于满足患者的需求，现在和未来。我们在 Teva 全力以赴，致力于更好的健康。要了解更多信息，请访问 www.tevapharm.com。</p>
<p><strong>Teva 关于前瞻性声明的警示说明</strong></p>
<p>除了历史信息外，本新闻稿还包含 1995 年《私人证券诉讼改革法案》所定义的前瞻性声明，包括但不限于关于我们财务指导的声明，这些声明基于管理层当前的信念和预期，并且受到已知和未知的重大风险和不确定性的影响，这可能导致我们的未来结果、表现或成就与这些前瞻性声明所表达或暗示的显著不同。这些前瞻性声明包括关于我们的计划、战略、目标、未来表现以及财务和运营目标的声明，以及任何其他非历史信息。您可以通过使用诸如 “应该”、“期望”、“预期”、“估计”、“目标”、“可能”、“项目”、“指导”、“打算”、“计划”、“相信” 等词语以及与未来运营或财务表现相关的其他类似含义和表达的词语来识别这些前瞻性声明。可能导致或促成这些差异的重要因素包括与以下内容相关的风险：我们在市场上成功竞争的能力，包括：我们在很大程度上依赖我们的仿制药产品；我们开发和商业化其他药品的能力；我们创新药物的竞争；我们从产品管道投资中获得预期结果的能力；我们成功执行 “增长转型” 战略的能力，包括扩大我们的创新药物和生物类似药管道并盈利性地商业化创新药物和生物类似药组合，无论是通过内部发展还是业务开发，以维持和专注于我们的仿制药组合，并执行我们的组织转型以实现预期的成本节约；以及我们专利和其他保护知识产权的措施的有效性；我们显著的债务，这可能限制我们承担额外债务、进行额外交易或进行新投资的能力；我们的一般业务和运营；合规、监管和诉讼事务；其他财务和经济风险；以及本文件中讨论的其他因素，在我们 2025 年第三季度的 10-Q 季度报告和截至 2024 年 12 月 31 日的 10-K 年度报告中，包括 “风险因素” 和 “前瞻性声明” 部分。前瞻性声明仅在作出之日有效，我们不承担更新或修订任何前瞻性声明或本文件中包含的其他信息的义务，无论是由于新信息、未来事件还是其他原因。请谨慎对待这些前瞻性声明。</p>
<p>Teva 媒体咨询 TevaCommunicationsNorthAmerica@tevapharm.com</p>
<p>Teva 投资者关系咨询 TevaIR@Tevapharm.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTFOalU0TXlNME1ESXpNRGd4TVRRak1qQXdNekEzTnc9PQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTFOalU0TXlNME1ESXpNRGd4TVRRak1qQXdNekEzTnc9PQ"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/ODE0ZDU2NjctYjJjNy00ZTQ3LWFjNDQtNjllMzFkNDFkYTQ4LTEwMTQ2NTAtMjAyNS0xMi0yNC1lbg==/tiny/Teva-Pharmaceutical-Industries.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/ODE0ZDU2NjctYjJjNy00ZTQ3LWFjNDQtNjllMzFkNDFkYTQ4LTEwMTQ2NTAtMjAyNS0xMi0yNC1lbg==/tiny/Teva-Pharmaceutical-Industries.png"/></p>

梯瓦制药

<p>标准普尔全球评级将梯瓦制药的信用评级从 “BB” 上调至 “BB+”，展望为稳定，同时穆迪将梯瓦的展望从稳定调整为积极，确认其 B1a 评级。这些升级反映了梯瓦在 “转型增长” 战略上的强劲执行、财务纪律和改善的杠杆水平，并预计将进一步降低杠杆。梯瓦的首席财务官强调了公司的战略愿景和对可持续增长的承诺。这些升级标志着朝着实现投资级别状态的进展，得益于品牌药物的强劲表现和仿制药的稳定</p>

<ul>
<li>The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline.</li>
<li>Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from stable</li>
<li>S&amp;P upgraded Teva to BB+ from BB, with a stable outlook</li>
</ul>
<div class="lb-trans"><ul>
<li>这两项更新强调了 Teva 在其 “转型增长” 战略中的强大执行力和对财务纪律的承诺。</li>
<li>穆迪确认了 Teva 的 B1a 评级，并将 Teva 的展望从稳定调整为积极。</li>
<li>标普将 Teva 的评级从 BB 上调至 BB+，展望为稳定。</li>
</ul>
</div><p>TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&amp;P Global Ratings (&#34;S&amp;P&#34;) has upgraded Teva’s long-term issuer credit rating to ‘BB+’ from ‘BB’, with a stable outlook, and that Moody's Ratings Agency (&#34;Moody's&#34;) affirmed Teva's B1a rating and revised Teva's outlook to positive from stable. These upgrades mark another significant milestone in Teva’s journey toward achieving investment-grade status.</p>
<div class="lb-trans"><p>以色列特拉维夫，2025 年 12 月 24 日（GLOBE NEWSWIRE）-- Teva 制药工业有限公司（纽约证券交易所和特拉维夫证券交易所：TEVA）今天宣布，标准普尔全球评级（&#34;S&amp;P&#34;）已将 Teva 的长期发行人信用评级从 ‘BB’ 上调至 ‘BB+’，展望为稳定，同时穆迪评级机构（&#34;Moody's&#34;）确认了 Teva 的 B1a 评级，并将 Teva 的展望从稳定调整为积极。这些升级标志着 Teva 在实现投资级别地位的旅程中的又一个重要里程碑。</p>
</div><p>The upgrades are underpinned by Teva’s consistent deleveraging trajectory, with S&amp;P noting that adjusted leverage declined to 4.4x as of September 30, 2025, and is expected to fall below 4.25x in the coming quarters, meeting the threshold for the higher rating. The ratings agency also highlighted Teva’s financial discipline, business strength and liquidity profile, returning to revenue growth after five years of declines, driven by robust performance in branded medicines and stabilization in generics.</p>
<div class="lb-trans"><p>这些升级得益于 Teva 持续的去杠杆化轨迹，标准普尔指出，截至 2025 年 9 月 30 日，调整后的杠杆率降至 4.4 倍，并预计在未来几个季度将降至 4.25 倍以下，符合更高评级的门槛。评级机构还强调了 Teva 的财务纪律、业务实力和流动性状况，在经历五年的下降后，重新实现了收入增长，这得益于品牌药物的强劲表现和仿制药的稳定。</p>
</div><p>Moody's cited Teva's continued improvement in operating performance and disciplined financial policies focused on debt reduction. The agency highlighted strong momentum in Teva’s branded franchises and upcoming product launches across both branded and biosimilar portfolios, which are expected to offset headwinds in the generics segment. Moody’s also noted Teva’s robust liquidity position, supporting its ability to manage upcoming debt maturities. Moody's stated that these factors, combined with expectations for leverage to decline toward 3.5x within 12–18 months, underpin the positive outlook and potential for an upgrade.</p>
<div class="lb-trans"><p>穆迪提到 Teva 在运营表现和专注于减债的财务政策方面的持续改善。该机构强调了 Teva 品牌业务的强劲势头以及即将推出的品牌和生物类似药产品，这些预计将抵消仿制药领域的逆风。穆迪还指出 Teva 的强大流动性状况，支持其管理即将到期的债务的能力。穆迪表示，这些因素，加上预计杠杆将在 12 至 18 个月内降至 3.5 倍的预期，支撑了积极的展望和升级的潜力。</p>
</div><p><strong>Eli Kalif, Teva's Chief Financial Officer, commented</strong>: &#34;This upgrade is a powerful testament to our strategic vision and disciplined execution, especially coming at the heels of multiple upgrades in recent months. By driving our Pivot to Growth strategy, prioritizing robust cash flow management, and rigorously allocating capital, we have demonstrated unwavering commitment to deleveraging and sustainable business growth. These results clearly show how our focused strategy is delivering tangible value for Teva and positioning us for continued success.&#34;</p>
<div class="lb-trans"><p><strong>Teva 首席财务官 Eli Kalif 评论道</strong>：&#34;这一升级是我们战略愿景和严谨执行的有力证明，尤其是在最近几个月多次升级之后。通过推动我们的转型增长战略，优先管理强劲的现金流，并严格分配资本，我们展示了对去杠杆化和可持续业务增长的坚定承诺。这些结果清楚地表明，我们的专注战略为 Teva 带来了切实的价值，并为我们持续的成功奠定了基础。&#34;</p>
</div><p><strong>About Teva</strong></p>
<div class="lb-trans"><p><strong>关于 Teva</strong></p>
</div><p>Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.</p>
<div class="lb-trans"><p>Teva 制药工业有限公司（纽约证券交易所和特拉维夫证券交易所：TEVA）正在转型为一家领先的创新生物制药公司，依托于世界一流的仿制药业务。120 多年来，Teva 对改善健康的承诺从未动摇。从在神经科学和免疫学领域的创新，到向全球提供复杂的仿制药、生物类似药和药房品牌，Teva 致力于满足患者的需求，现在和未来。我们在 Teva 全力以赴，致力于更好的健康。要了解更多信息，请访问 www.tevapharm.com。</p>
</div><p><strong>Teva Cautionary Note Regarding Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>Teva 关于前瞻性声明的警示说明</strong></p>
</div><p>In addition to historical information, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial guidance, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this document, in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned “Risk Factors” and “Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.</p>
<div class="lb-trans"><p>除了历史信息外，本新闻稿还包含 1995 年《私人证券诉讼改革法案》所定义的前瞻性声明，包括但不限于关于我们财务指导的声明，这些声明基于管理层当前的信念和预期，并且受到已知和未知的重大风险和不确定性的影响，这可能导致我们的未来结果、表现或成就与这些前瞻性声明所表达或暗示的显著不同。这些前瞻性声明包括关于我们的计划、战略、目标、未来表现以及财务和运营目标的声明，以及任何其他非历史信息。您可以通过使用诸如 “应该”、“期望”、“预期”、“估计”、“目标”、“可能”、“项目”、“指导”、“打算”、“计划”、“相信” 等词语以及与未来运营或财务表现相关的其他类似含义和表达的词语来识别这些前瞻性声明。可能导致或促成这些差异的重要因素包括与以下内容相关的风险：我们在市场上成功竞争的能力，包括：我们在很大程度上依赖我们的仿制药产品；我们开发和商业化其他药品的能力；我们创新药物的竞争；我们从产品管道投资中获得预期结果的能力；我们成功执行 “增长转型” 战略的能力，包括扩大我们的创新药物和生物类似药管道并盈利性地商业化创新药物和生物类似药组合，无论是通过内部发展还是业务开发，以维持和专注于我们的仿制药组合，并执行我们的组织转型以实现预期的成本节约；以及我们专利和其他保护知识产权的措施的有效性；我们显著的债务，这可能限制我们承担额外债务、进行额外交易或进行新投资的能力；我们的一般业务和运营；合规、监管和诉讼事务；其他财务和经济风险；以及本文件中讨论的其他因素，在我们 2025 年第三季度的 10-Q 季度报告和截至 2024 年 12 月 31 日的 10-K 年度报告中，包括 “风险因素” 和 “前瞻性声明” 部分。前瞻性声明仅在作出之日有效，我们不承担更新或修订任何前瞻性声明或本文件中包含的其他信息的义务，无论是由于新信息、未来事件还是其他原因。请谨慎对待这些前瞻性声明。</p>
</div><p>Teva Media Inquiries TevaCommunicationsNorthAmerica@tevapharm.com</p>
<div class="lb-trans"><p>Teva 媒体咨询 TevaCommunicationsNorthAmerica@tevapharm.com</p>
</div><p>Teva Investor Relations Inquiries TevaIR@Tevapharm.com</p>
<div class="lb-trans"><p>Teva 投资者关系咨询 TevaIR@Tevapharm.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTFOalU0TXlNME1ESXpNRGd4TVRRak1qQXdNekEzTnc9PQ" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE1NjU4MyM0MDIzMDgxMTQjMjAwMzA3Nw=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/ODE0ZDU2NjctYjJjNy00ZTQ3LWFjNDQtNjllMzFkNDFkYTQ4LTEwMTQ2NTAtMjAyNS0xMi0yNC1lbg==/tiny/Teva-Pharmaceutical-Industries.png" alt="" original-src="https://ml-eu.globenewswire.com/media/ODE0ZDU2NjctYjJjNy00ZTQ3LWFjNDQtNjllMzFkNDFkYTQ4LTEwMTQ2NTAtMjAyNS0xMi0yNC1lbg==/tiny/Teva-Pharmaceutical-Industries.png"/></p>

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive | TEVA Stock News

标普全球评级将梯瓦制药的评级上调至 ‘BB+’，因为其在实施转向增长战略方面表现出色；穆迪评级机构将其展望调整为正面 | TEVA 股票新闻